JP2020502280A - 置換ポルフィリン医薬化合物及び組成物を製造する方法 - Google Patents

置換ポルフィリン医薬化合物及び組成物を製造する方法 Download PDF

Info

Publication number
JP2020502280A
JP2020502280A JP2019554488A JP2019554488A JP2020502280A JP 2020502280 A JP2020502280 A JP 2020502280A JP 2019554488 A JP2019554488 A JP 2019554488A JP 2019554488 A JP2019554488 A JP 2019554488A JP 2020502280 A JP2020502280 A JP 2020502280A
Authority
JP
Japan
Prior art keywords
compound
formula
composition
pyridyl
anion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019554488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502280A5 (enExample
Inventor
バティニック−ハベルレ，イネス
トブマシャン，アルタック
ラジック ドゾリック，ズリンカ
ラジック ドゾリック，ズリンカ
スパソジェヴィック，アイヴァン
アレン リー，クリストファー
アレン リー，クリストファー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2020502280A publication Critical patent/JP2020502280A/ja
Publication of JP2020502280A5 publication Critical patent/JP2020502280A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B47/00—Formation or introduction of functional groups not provided for in groups C07B39/00 - C07B45/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2019554488A 2016-12-20 2017-12-19 置換ポルフィリン医薬化合物及び組成物を製造する方法 Pending JP2020502280A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662436743P 2016-12-20 2016-12-20
US62/436,743 2016-12-20
PCT/US2017/067263 WO2018118891A1 (en) 2016-12-20 2017-12-19 Methods of making substituted porphyrin pharmaceutical compounds and compositions

Publications (2)

Publication Number Publication Date
JP2020502280A true JP2020502280A (ja) 2020-01-23
JP2020502280A5 JP2020502280A5 (enExample) 2021-02-04

Family

ID=62628012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019554488A Pending JP2020502280A (ja) 2016-12-20 2017-12-19 置換ポルフィリン医薬化合物及び組成物を製造する方法

Country Status (8)

Country Link
US (1) US20190330220A1 (enExample)
EP (1) EP3558902A4 (enExample)
JP (1) JP2020502280A (enExample)
KR (1) KR20190098211A (enExample)
CN (1) CN110291060A (enExample)
CA (1) CA3046357A1 (enExample)
MX (1) MX2019007301A (enExample)
WO (1) WO2018118891A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536055A (ja) * 2017-09-29 2020-12-10 デューク ユニバーシティ フルオロ置換ポルフィリン化合物、該化合物を含む医薬組成物、並びに該化合物を調製及び使用する方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187411A1 (en) * 2017-04-04 2018-10-11 Biomimetix Jv, Llc Methods, compositions, and kits for treating and/or preventing a side effect associated with radiation and/or chemotherapy exposure

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535332A (ja) * 1999-01-25 2002-10-22 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター 置換ポルフィリン
WO2005077269A1 (en) * 2004-02-09 2005-08-25 Duke University Substituted porphyrins
JP2006501163A (ja) * 2002-06-07 2006-01-12 デューク・ユニバーシティー 置換ポルフィリン
WO2010080881A1 (en) * 2009-01-07 2010-07-15 Duke University Substituted porphyrins
WO2010138633A1 (en) * 2009-05-26 2010-12-02 Duke University Method of providing neuroprotection using substituted porphyrins
WO2015112586A1 (en) * 2014-01-22 2015-07-30 Duke University Methods of treating pruritus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535332A (ja) * 1999-01-25 2002-10-22 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター 置換ポルフィリン
JP2006501163A (ja) * 2002-06-07 2006-01-12 デューク・ユニバーシティー 置換ポルフィリン
WO2005077269A1 (en) * 2004-02-09 2005-08-25 Duke University Substituted porphyrins
WO2010080881A1 (en) * 2009-01-07 2010-07-15 Duke University Substituted porphyrins
WO2010138633A1 (en) * 2009-05-26 2010-12-02 Duke University Method of providing neuroprotection using substituted porphyrins
WO2015112586A1 (en) * 2014-01-22 2015-07-30 Duke University Methods of treating pruritus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARTAK TOVMASYAN; ET AL: "RATIONAL DESIGN OF SUPEROXIDE DISMUTASE (SOD) MIMICS: THE EVALUATION OF THE THERAPEUTIC 以下備考", INORGANIC CHEMISTRY, vol. VOL:53, NR:21, JPN5020002148, 21 October 2014 (2014-10-21), pages 11467 - 11483, ISSN: 0004805975 *
RAJIC, ZRINKA; TOVMASYAN, ARTAK; SPASOJEVIC, IVAN; SHENG, HUAXIN; LU, MIAOMIAO; LI, ALICE M.; GRALLA: "A new SOD mimic, Mn(III) ortho N-butoxyethylpyridylporphyrin, combines superb potency and lipophi", FREE RADICAL BIOLOGY & MEDICINE, vol. 52(9),, JPN6021045193, 2012, pages 1828 - 1834, ISSN: 0004805974 *
TOVMASYAN, ARTAK ET. AL.: "Anticancer therapeutic potential of Mn porphyrin/ascorbate system", FREE RADICAL BIOLOGY & MEDICINE, vol. 89,, JPN6021045195, 2015, pages 1231 - 1247, ISSN: 0004805976 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536055A (ja) * 2017-09-29 2020-12-10 デューク ユニバーシティ フルオロ置換ポルフィリン化合物、該化合物を含む医薬組成物、並びに該化合物を調製及び使用する方法
JP7336805B2 (ja) 2017-09-29 2023-09-01 デューク ユニバーシティ フルオロ置換ポルフィリン化合物、該化合物を含む医薬組成物、並びに該化合物を調製及び使用する方法

Also Published As

Publication number Publication date
KR20190098211A (ko) 2019-08-21
US20190330220A1 (en) 2019-10-31
CA3046357A1 (en) 2018-06-28
CN110291060A (zh) 2019-09-27
EP3558902A1 (en) 2019-10-30
EP3558902A4 (en) 2020-06-24
WO2018118891A1 (en) 2018-06-28
MX2019007301A (es) 2019-10-30

Similar Documents

Publication Publication Date Title
KR102548191B1 (ko) 표적 단백질 분해 화합물, 이의 항종양 응용, 이의 중간체 및 중간체의 응용
CN111065639B (zh) 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
US11091476B2 (en) Protein kinase inhibitors, preparation method and medical use thereof
KR102762016B1 (ko) 니트록솔린 전구약물 및 이의 용도
WO2015031564A2 (en) Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors
EA024681B1 (ru) Имидазопиридины в качестве противовирусных средств против респираторно-синцитиального вируса
KR102442536B1 (ko) 리나글립틴 결정형 및 이의 제조방법
EP2829545A1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2021120401A (ja) 水溶性プロドラッグ
WO2013006734A1 (en) Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
CA2561733A1 (en) Pegylated ion channel modulating compounds
JP2020502280A (ja) 置換ポルフィリン医薬化合物及び組成物を製造する方法
AU2016307230B2 (en) Compounds
EP2445899B1 (en) Novel fumarate salts of a histamine h3 receptor antagonist
DK2610257T3 (en) DI-IMIDED DERIVATIVE OF BERBAMINE AND METHOD FOR PREPARING AND USING THEREOF
JP2006514064A (ja) ポルフィリン誘導体
US6825193B2 (en) Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof
KR20210134306A (ko) 아크릴-함유 핵 수출 조절제들 및 이들의 용도들
JP2023546584A (ja) Ｅｒ陽性がんに選択的な抗がん化合物
KR20230144686A (ko) 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도
EP3498712B1 (en) Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof
JP2022523742A (ja) 二環式ピリジン組成物およびがんの治療にそれを使用する方法
CN100439372C (zh) 卟啉衍生物
CN110627665B (zh) 一种新的文拉法辛衍生物及其制备方法和应用
WO2024230825A1 (en) Novel compounds as cyp11a1 inhibitors and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220622